Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

216

total

1,044.403

impact factor

4.853

average impact factor

Director: Ricardo Pujol Borrell

team

zoom

download

The application of massive sequencing to primary immunodeficiencies started to bear fruits during 2017, improving diagnosis and treatment of patients and placing the group in the first line of European research. This departure was made possible by the continuous support of ISCIII which in 2017 approved a new project, this in collaboration with Dr Sayos (VHIR) and also of the Division of Genetics of the Hospital (Dr E. Tizzano) and of the Banc de Sang i Texits (Dr. F. Vidal). This line of research is the result of close collaborations with the clinical group “Infection in immunocompromised paediatric patient” (Dr Pere Soler-Palacin) and with other clinical divisions (e.g., hematology, pneumology).

On the line of autoimmunity, the study of the so-called Negative Checkpoint Receptors e.g PD1, PDL1, has prompted the generation of new projects in both endocrine autoimmunity and tumour immunotherapy with the Oncology Division (also funded by the ISCIII). The first results were presented at congresses with publications still in preparation

Finally, the inter-disciplinary VHIR traslational immunology program was approved in 2017. The program is expected to improve markedly research and generate results applicable to patients with immunomediated diseases.

5

total

31^.203

impact factor

6^.241

average impact factor

SELECTED ARTICLES

Speckmann C, Doerken S, Aiuti A, Albert MH, Al-Herz W, Allende LM, Scarselli A, Avcin T, Perez-Becker R, Cancrini C, Cant A, Di Cesare S, Finocchi A, Fischer A, Gaspar HB, Ghosh S, Gennery A, Gilmour K, Gonzalez-Granado LI, Martinez-Gallo M, Hambleton S, Hauck F, Hoenig M, Moshous D, Neven B, Niehues T, Notarangelo L, Picard C, Rieber N, Schulz A, Schwarz K, Seidel MG, Soler-Palacin P, Stepensky P, Strahm B, Vraetz T, Warnatz K, Winterhalter C, Worth A, Fuchs S, Uhlmann A, Ehl S. A prospective study on the natural history of patients with profound combined immunodeficiency: An interim analysis. J Allergy Clin Immunol. 2017 Apr;139(4):1302-1310.e4. doi: 10.1016/j.jaci.2016.07.040. Epub 2016 Sep 19.

Franco-Jarava C, Alvarez de la Campa , Solanich X, Morandeira-Rego F, Mas-Bosch V, Garcia-Prat M, de la Cruz X, Martin-Nalda A, Soler-Palacin P, Hernandez-Gonzalez M, Colobran R. Early Versus Late Diagnosis of Complement Factor I Deficiency: Clinical Consequences Illustrated in Two Families with Novel Homozygous CFI Mutations. J Clin Immunol. 2017 Nov;37(8):781-789. doi: 10.1007/s10875-017-0447-x. Epub 2017 Sep 23.

Pseudomonas aeruginosa Liver Abscess as the First Manifestation of X-Linked Agammaglobulinemia With a Novel Mutation. Munoz-Miguelsanz MA, Alvarez Morales T, Martin Garcia JA, Martinez Gallo M, Santos Perez JL. J Investig Allergol Clin Immunol. 2017;27(2):129-131. doi: 10.18176/jiaci.0129.

Franco-Jarava C, Comas D, Orren A, Hernandez-Gonzalez M, Colobran R. Complement factor 5 (C5) p.A252T mutation is prevalent in, but not restricted to, Sub-Saharan Africa: Implications for the susceptibility to meningococcal disease. Clin Exp Immunol. 2017 Aug;189(2):226-231. doi: 10.1111/cei.12967. Epub 2017 Apr 20.

Bernal-Bello D, de Tena JG, Guillen-Del Castillo, Selva-O’Callaghan A, Callejas-Moraga EL, Marin-Sanchez AM, Fonollosa-Pla V, Simeon-Aznar CP. Novel risk factors related to cancer in sclerodermia. Autoimmun Rev. 2017 May;16(5):461-468. doi: 10.1016/j.autrev.2017.03.012. Epub 2017 Mar 8.

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Director: Ricardo Pujol Borrell

Research Areas